CHPA Requests Extension To Childproof Imidazoline Product Packaging
This article was originally published in The Tan Sheet
The OTC trade group says firms need two years, twice the time CPSC would allow under a proposed rule, to require child-resistant packaging for drugs with more than 0.08 mg of imidazolines, including such OTCs as Visine eye drops and Afrin nasal decongestants.
You may also be interested in...
Watson acquires Australian OTC firm; childproof packaging for imidazoline; Supplement Facts box update delayed; more news In Brief
J&J reports worldwide consumer sales dipped 0.6% to $3.6 billion despite retailers buying more upper respiratory and analgesic products to prepare for the cough and cold season. But in key OTC categories the firm is regaining market share it lost when its iconic brands were temporarily not available.
GlaxoSmithKline restructures its management to ensure adequate focus on its three core areas, pharmaceutical, vaccine and consumer. Consumer product sales fell 3% to $1.72 billion in the third quarter due to continuing supply interruptions and generally weaker markets.